Urinary Tract Cancer Market 2022 Latest Study Focuses On Current, Future Innovations and Foreseen by Exelixis, Inc., GlaxoSmithKline Plc. (GSK), Merck KGAA

📌 Overview of the Urinary Tract Cancer Market:

Urinary tract cancer is most common in young adults and is found in women older than 50 years. Many cases are multicentric and associated with concurrent bladder cancer. Twenty-four percent of patients diagnosed with upper tract cancer also had a tumor on the opposite side. A bladder tumor is more likely to have a high risk of transitional cell cancer, while cancer in the upper urinary tract is less likely to occur in the lower urinary tract. Despite this, a large proportion of patients with UC develop both types of upper tract tumors.

Rising prevalence of bladder cancer around the globe is a prime factor fueling the market growth of urinary tract cancer. The American Cancer Society’s estimates for bladder cancer in the United States for 2021 are: about 83,730 new cases of bladder cancer (about 64,280 in men and 19,450 in women) and about 17,200 deaths from bladder cancer (about 12,260 in men and 4,940 in women) Increasing focus of key players to improve distribution channel for bladder cancer drug is again fostering growth of the market. For instance, in May 2018, Ferring signs global agreement to commercialize novel gene therapy for bladder cancer patients who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy.

Purchase the Complete Urinary Tract Cancer Market Research Report at https://www.stratagemmarketinsights.com/cart/42743

North America is expected to witness significant growth over the forecast period owing to the increasing launch of new drugs for the treatment of urinary tract cancer. For instance, in April 2019, The U.S. Food and Drug Administration granted approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2.

📌 Key Developments:

❖ In June 2020, EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt and Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC)

❖ In April 2020, The US Food and Drug Administration (FDA) approved Jelmyto (mitomycin gel) for a type of urothelial cancer, which is a cancer of the lining of the urinary system.

❖ In April 2018, Global pharma major Roche has launched monoclonal antibody atezolizumab under the brand name Tecentriq in India for treatment of lung and bladder cancer.

📌 The Leading Players involved in the global Urinary Tract Cancer market are:

❖ Astellas Pharma Inc.
❖ Bristol-Myers Squibb Company
❖ Eli Lily and Company
❖ Endo International plc.
❖ Exelixis, Inc.
❖ GlaxoSmithKline Plc. (GSK)
❖ Merck KGAA
❖ Novartis AG
❖ Pfizer Inc.
❖ Johnson & Johnson

📌 The Study Explore the Product/Types of the Market:

❖ Bladder Cancer
❖ Urethral cancer
❖ Ureteric and Renal Pelvic Cancer

📌 Key Applications/End-users of the Market:

❖ Chemotherapy
❖ Retail Pharmacy
❖ Online Pharmacy
❖ Immunotherapy
❖ Retail Pharmacy
❖ Online Pharmacy

📌 Regions/Country Included are:

❖ The Middle East and Africa (Turkey, GCC Countries, Egypt, South Africa)
❖ North America( United States, Mexico, and Canada)
❖ South America (Brazil, etc.)
❖ Europe (Germany, Russia, UK, Italy, France, etc.)
❖ Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

In the latest industry analysis by Stratagem Market Insights (SMI), the growth of the Urinary Tract Cancer market is projected to expand at a driving CAGR through 2028 as the global market grows gradually recovers. The report aims to provide insight into hidden growth opportunities and challenges. It also provides recommendations for businesses to prepare for unexpected problems. This newly published insightful report sheds light on the market insights of the Urinary Tract Cancer, its key dynamics, its impact across the value chain from suppliers/service providers to end-users, and the growth of the Urinary Tract Cancer market.

To remain ‘ahead’ of your competitors, request a sample @ https://www.stratagemmarketinsights.com/sample/42743

The study provides pragmatic and valuable market insights into the Urinary Tract Cancer. Additionally, the latest report offers details on the current scenario of the market across different regions along with historical data and forecasts (2022-2028) of the market. The report also includes information on sales and demand for the Urinary Tract Cancer market across various industries and regions.

The research conducted by SMI provides exclusive information on how the market is growing. The study identifies essential trends determining the growth of the Urinary Tract Cancer market. This newly published report sheds light on vital dynamics such as drivers, restraints, and opportunities of leading market players as well as emerging players associated with the production/services and supply.

📌 Report Benefits & Key Questions Answered:

✔ Urinary Tract Cancer Market Companies and Share Analysis: The report offers a detailed Urinary Tract Cancer market share analysis to estimate the market proportions covered by Tier 1, Tier 2, and Tier3 companies.

✔ Urinary Tract Cancer Market Historical Volume Analysis: The report provides a comparative analysis of the Urinary Tract Cancer's historical sales and 2022-2028 forecasted sales performance.

✔ Urinary Tract Cancer market Category and Segment Level Analysis: SMI provides a comprehensive analysis of the factors enabling revenue growth across key segments. It highlights key growth drivers and provides valuable information to understand sales prospects at local and regional levels.

✔ Urinary Tract Cancer Consumption by Demographics: The report studies consumer behavior and consumption patterns to provide informed recommendations. Demographic analysis is intended to help businesses better understand consumer preferences and design products/services and market strategies around them.

✔ Post-COVID Consumer Spending for Urinary Tract Cancer: Market research carefully examines consumer spending behavior post-COVID-19. It measures how general trends influence their behavior and subsequently their spending power.

Purchase this exclusive report to access full information @ https://www.stratagemmarketinsights.com/cart/42743

📌 Reasons why you should buy this report:

➥ Understand the Current and future of the Urinary Tract Cancer Market in both Established and emerging markets.
➥ The report assists in relocating the business strategies by accentuating the Urinary Tract Cancer business priorities.
➥ The report throws light on the segment anticipated to dominate the Urinary Tract Cancer industry and market.
➥ Forecasts the regions expected to perceive ascension.
➥ The newest developments within the Urinary Tract Cancer industry and details of the industry leaders alongside their market share and methods.
➥ Saves time on the entry-level research as the report contains significant data concentrating growth, size, key players, and segments of the industry.
➥ Save time carrying out entry-level research by characterizing the growth, size, major players, and segments within the Global Market.

In addition, the following years are taken into account for the study:
Historic year - 2015-2020
Base year - 2021
Forecast period ** - 2022-2028 [** unless otherwise stated]

** It also includes a detailed analysis of the competitive landscape, the opportunities available in the micro-market that stakeholders can invest in, and the product services of key players.

Contact Us:

Stratagem Market Insights
1001 4th Ave, #3200 Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027 / JAPAN +815055391737
Email: sales@stratagemmarketinsights.com
SJ

About Us:

Stratagem Market Insights is a management consulting organization providing market intelligence and consulting services worldwide. We bring the expertise of consultants with a cumulative industry experience of more than 70 years. The firm has been providing quantified B2B research and currently offers services to over 350+ customers worldwide.

This release was published on openPR.